These findings offer a comprehensive atlas of CAF heterogeneity in glioma and highlight the therapeutic promise of targeting apCAF–M2 macrophage interactions or AQP4 to over-come immune resistance and improve clinical outcomes. This evidence concerns the gene AQP4 and central nervous system cancer.